Liver histology during Mipomersen therapy for severe hypercholesterolemia

Journal of Clinical Lipidology

Volumn 8, Issue 6, 2014, Pages 606-611

  Hashemi, Nikroo ^a   Odze, Robert D ^a   McGowan, Mary P ^b,c   Santos, Raul D ^d   Stroes, Erik S G ^e   Cohen, David E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GENZYME CORPORATION   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antisense oligonucleotide; Apolipoprotein B; Cholesterol; Fibrosis; Inflammation; LDL; Liver; Nonalcoholic fatty liver disease; Steatohepatitis; Triglycerides; VLDL

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; COLESEVELAM; EZETIMIBE; FENOFIBRATE; FISH OIL; MIPOMERSEN; NICOTINIC ACID; PLACEBO; ROSUVASTATIN; SIMVASTATIN; APOLIPOPROTEIN B; FATTY ACID; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIGONUCLEOTIDE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATTY LIVER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LIVER BIOPSY; LIVER HISTOLOGY; LIVER INJURY; MACROSTEATOSIS; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEATOSIS; BIOPSY; BLOOD; CHEMICALLY INDUCED; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFECTS; FIBROSIS; GENETICS; LIVER; METABOLISM; NONALCOHOLIC FATTY LIVER; PATHOLOGY;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BIOPSY; CHOLESTEROL, LDL; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FATTY ACIDS; FATTY LIVER; FEMALE; FIBROSIS; HUMANS; HYPERCHOLESTEROLEMIA; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OLIGONUCLEOTIDES; TRIGLYCERIDES;

EID: 84928828932     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.08.002     Document Type: Article

References (17)

1. F. Akdim, M.E. Visser, D.L. Tribble, and et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia Am J Cardiol 105 2010 1413 1419
2. G.S. Thomas, W.C. Cromwell, S. Ali, W. Chin, J.D. Flaim, and M. Davidson Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 62 2013 2178 2184
3. M.E. Visser, F. Akdim, D.L. Tribble, and et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia J Lipid Res 51 2010 1057 1062
4. M.E. Visser, G. Wagener, B.F. Baker, and et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial Eur Heart J 33 2012 1142 1149
5. F.J. Raal, R.D. Santos, D.J. Blom, and et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
6. E.A. Stein, R. Dufour, C. Gagne, and et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 126 2012 2283 2292
7. M.P. McGowan, J.C. Tardif, R. Ceska, and et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS One 7 2012 e49006
8. R.D. Santos, P.B. Duell, C. East, and et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension Eur Heart J 2013 [Epub ahead of print]
9. D.J. Rader, and J.J. Kastelein Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia Circulation 129 2014 1022 1032
10. M. Cuchel, L.T. Bloedon, P.O. Szapary, and et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 356 2007 148 156
11. M. Cuchel, E.A. Meagher, H. du Toit Theron, and et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 2013 40 46
12. A.H. Paredes, D.M. Torres, and S.A. Harrison Nonalcoholic fatty liver disease Clin Liver Dis 16 2012 397 419
13. D.E. Cohen, and E.A. Fisher Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease Semin Liver Dis 33 2013 380 388
14. T. Tanoli, P. Yue, D. Yablonskiy, and G. Schonfeld Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity J Lipid Res 45 2004 941 947
15. A. Lonardo, S. Lombardini, F. Scaglioni, and et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 44 2006 190 196
16. M.E. Visser, N.M. Lammers, A.J. Nederveen, and et al. Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia Diabetologia 54 2011 2113 2121
17. F.M. Sacks, M. Stanesa, and R.A. Hegele Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide JAMA Intern Med 174 2014 443 447